CRISPR Therapeutics AG

Some of the best links we picked up around the internet

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

CMN Weekly (17 January 2025) - Your Weekly CRISPR...

CMN Weekly

Jan. 17, 2025

Some of the best links we picked up around the internet

CMN Weekly (13 December 2024) - Your Weekly CRISPR...

CMN Weekly

Dec. 13, 2024

Some of the best links we picked up around the internet

CMN Weekly (29 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 29, 2024

Some of the best links we picked up around the internet

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

CMN Weekly (9 August 2024) - Your Weekly CRISPR...

CMN Weekly

Aug. 9, 2024

Some of the best links we picked up around the internet

CMN Weekly (10 May 2024) - Your Weekly CRISPR...

CMN Weekly

May. 10, 2024

Some of the best links we picked up around the internet

CRISPR Therapeutics AG

Relapsed/Refractory Hematologic Malignancies (NCT06492304)
Sponsors:
CRISPR Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Hematologic and Solid Malignancies, (NCT06208878)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Cardiovascular Disease or Calcific Aortic Valve Stenosis, (ACTRN12623001095651p)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Refractory Dyslipidemias, (ACTRN12623000809639)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Solid Tumors, (NCT05795595)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies, (NCT05643742)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Type 1 Diabetes, T1D, (NCT05565248)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III